Could an arthritis pill ease Sjogren's? new trial seeks answers

NCT ID NCT07281456

Recruiting now Disease control Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether tofacitinib, a drug already used for rheumatoid arthritis, is safe and helpful for people with Sjogren's disease. About 60 adults with mild-to-moderate Sjogren's will take the pill twice daily for 28 weeks. Researchers will track side effects and measure changes in symptoms like dry eyes, joint pain, and overall disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tofacitinib (a pill that calms the immune system, already approved for rheumatoid arthritis)
What this could lead to: If it works, this could point toward a new treatment option for people with Sjogren's disease, helping control symptoms like dry eyes, joint pain, and fatigue.
What could go wrong: This is an early phase 2 trial with only 60 people, so results may not apply to everyone. Tofacitinib can increase risk of infections and other side effects, and it may not work for Sjogren's as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation Sjogren syndrome xerophthalmia Xerostomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJOGREN'S SYNDROME

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.